about half of hypertensive patients have control of their blood pressure, 1 which leaves a substantial proportion of the population at an increased, but modifiable, risk of MACEs.
Monotherapy is the recommended initial approach for reducing blood pressure, except for stage II hypertension (blood pressure Ն160/100 mmHg). 5 While some individuals can achieve control of their blood pressure and bring it to guideline-recommended levels using a single medication, 63% of 12,210 patients with a 5-year visit in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) required Ն2 agents. 6 Another strategy for treating hypertension is the use of combination therapy: either a fixed-dose combination (FDC), which combines 2 active agents into a single pill, or a free-equivalent combination (FEC), which is the separate use of the corresponding single-agent pills. Several efficacy trials have previously shown combination therapy to be more effective than monotherapy in achieving blood pressure control, but we have found no randomized control trials that explicitly evaluated differences in efficacy between the 2 combination strategies. [7] [8] [9] Other studies, however, have shown that patients using an FDC have greater adherence to and persistence with medication regimens compared with patients using an FEC. 10, 11 The objectives of the present study were to (1) assess the comparative effectiveness of several antihypertensive therapeutic classes initiated as monotherapy, and (2) compare the effectiveness of the initial use of 3 treatment strategies (monotherapy, FDC, and FEC) in hypertensive patients receiving care in a diverse primary care setting.
Methods

Data Source
This study was conducted using data from primary care clinics participating in the Distributed Ambulatory Research in Therapeutics Network (DARTNet) collaborative, a federated network of electronic health record (EHR) data that has as one of its objectives the facilitation of observational comparative effectiveness research. [12] [13] [14] DARTNet, in collaboration with QED Clinical, Inc. (doing business as CINA; http://www.cina-us.com/), has developed data extraction, transformation, and loading (ETL) processes that allow aggregation of data from disparate EHRs into a limited database. All data were imported nightly from the organization EHR to a relational clinical data repository (CDR) located behind the firewall of each organization. The CINA software used for ETL was already in place and being used by each organization to produce reports of clinical decision support and population management at the point of care.
Data validation was largely the responsibility of CINA, as the ETL vendor in place at each organization before the initiation of this project. Because CINA provides software tools that utilize data from the CDR in the course of clinical care and decision making, CINA has several processes in place to ensure the reliability and validity of the data that is contained within the CDR. Data reliability testing by CINA includes the following: (1) patient-level sampling comparing the data imported into the CDR with the source data as it is represented in the EHR; (2) daily use of the data in the CDR in clinical practice through the point-of-care clinical decision support tool and population management tools provided by CINA; and (3) data reliability testing with data extraction for research analysis.
The DARNet Cardiovascular Risk Reduction Learning Community was designed to provide patient-specific clinical decision support at the point of care and an audit with feedback on national guidelines (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [JNC7]) for the control of blood pressure (unpublished data). The Cardiovascular Risk Reduction Learning Community limited data set obtained from the DARTNet collaborative also was used for the current study, which includes 33 primary care clinics from 10 health organizations and approximately 154 clinicians providing care to more than 250,000 patients.
Data use agreements for access to the limited data set were obtained from each organization, and a waiver of informed consent and Health Insurance Portability and Accountability Act authorization were approved by the American Academy of Family Physicians' institutional review board and the Colorado Multiple Institutional Review Board of the University of Colorado Denver.
Data Collection and Cleaning
The data used in the present analyses included patient demographics, height, weight, blood pressure, comorbidities (International Classifica-tion of Diseases, 9th revision, codes from the problem lists and reasons for visit), medications, laboratory data, and dates of encounters between August 2001 and August 2011. Data on patient race/ethnicity and frequency of medication dosing were sparsely populated and were not included in our analyses.
For continuous variables, physiologically implausible values were identified by clinicians examining the distributions of the variables. These consensus-derived, physiologically implausible values were systolic blood pressure Ͻ50 or Ͼ260 mm Hg, diastolic blood pressure Ͻ0 or Ͼ200 mm Hg, height Ͻ45 or Ͼ90 inches, weight Ͻ50 or Ͼ500 lb, and serum creatinine Ͻ0.2 or Ͼ20 mg/dL and were excluded in the current study. The proportion of values deleted varied from 0.005% for systolic blood pressure to 0.5% for serum creatinine. In addition, height and weight were missing for 4.2% and 0.3% of patients, respectively, and were replaced with sex-specific mean values for height (women, 63.9 inches; men, 69.8 inches) and weight (women, 178.9 lb; men, 212.9 lb). Figure 1 defines the inclusion criteria for this study. The index date was defined as the date of the first prescription of an antihypertensive agent, before which the patient had been followed with no antihypertensive prescriptions for Ն12 months. The index blood pressure was the value closest to and falling within the 2-month Figure 1 . Timeline defining key events in the study for patients initially using antihypertensive agents. BP, blood pressure; Rx, prescription. interval before the initiation of antihypertensive therapy. If the patient's treatment was classified as FEC, the second drug must have been started within 3 days of the first. The blood pressure value used to assess reduction and goal attainment from the index pressure was the one with the latest date/time stamp within the time period of 1 week to 1 year following the index time point during which no change had been made in the antihypertensive drug regime. Figure 2 shows the STROBE diagram for inclusion of patients in our analyses. There were 79,176 patients Ն18 years old who were receiving at least one antihypertensive agent. Exclusions were as follows: (1) 51,454 patients classified as prevalent users of antihypertensive agents because there was no period Ն12 months in duration when they received no antihypertensive agents; (2) 4,391 patients who had no blood pressure measured in the 2 months before initiation of antihypertensive therapy; (3) 10,711 patients whose blood pressure was at goal in the 2 months before initiating antihypertensive therapy; (4) 2,451 patients taking Ն3 antihypertensive agents; and (5) 1,493 patients with no blood pressure measurements available following the initiation of antihypertensive therapy. The final analytic subset consists of 8,676 patients (11.0%) of the 79,176 patients Ն18 years old who had received at least one prescription for an antihypertensive agent and had elevated blood pressures (as defined by the JNC7) before or on the index date. The outcomes evaluated in this study were changes in follow-up systolic and diastolic blood pressures from index blood pressures and JNC7 therapeutic goal attainment rates at follow-up.
Definitions
Patient Inclusion
Statistical Analyses
To characterize the study population, we calculated descriptive statistics using means and standard deviations for continuous variables and compared the different antihypertensive therapeutic classes using analyses of variance. For categorical variables, frequencies and percentages were calculated and lo- gistic regression was used to compare patient characteristics between the groups.
We used analysis of covariance to model mean reductions in blood pressures and logistic regression to compare the proportion of patients achieving blood pressure control in each group. To account for patient differences, we constructed multivariable prediction models using the covariates listed in Table 1 , which were chosen using clinical judgment and prior research. All covariates were included in each risk-adjusted model, except in the case of mean reductions in blood pressures, for which baseline diastolic blood pressure was not included in the model of mean reductions in systolic blood pressure and vice versa. Hierarchical linear models including clinic and organization also were evaluated and gave similar results (data not shown).
Risk-adjusted outcomes for each antihypertensive therapeutic class were calculated from predicted values obtained from models fitted with covariates only. Means and standard deviations of the predicted values were calculated to obtain riskadjusted average reductions in blood pressures. For risk-adjusted control rates, expected rates of control for each antihypertensive therapeutic class were compared with the observed rates of control as an observed-to-expected ratio, which was converted to standardized rates by multiplying each observed-to-expected ratio by the observed rate of control for all patients across all antihypertensive therapeutic classes.
For all outcomes, P values were adjusted for multiple tests using the Bonferroni method. All statistical tests were considered to be significant at a 2-sided P Ͻ .05. All analyses were performed using SAS software version 9.3 (SAS Inc., Cary, NC).
Results
Population Characteristics
The population characteristics for all 8676 patients initially using antihypertensives in primary care are shown in Table 1 . They tended to be middle-aged and overweight, and slightly less than a quarter of the patient had either diabetes or CKD requiring lower blood pressure goals. Only 61% had a diagnosis of hypertension. The median follow-up duration was a little more than 6 months and, in general, the patients had approximately 3 clinic visits in the year before index date.
Population characteristics stratified by therapeutic class are presented in Table 2 and by treatment strategy in Table 3 . The proportions and mean values for essentially all risk factors differed significantly across therapeutic classes and treatment strategies. The prevalence of CKD was greater in those initiated on a ␤-blocker (11.5%), ARB (9.8%), and CCB (17.8%) compared with an ACEI (7.1%) or a thiazide (6.5%), and patients with diabetes and hyperlipidemia tended to receive an ACEI (25.2% and 37.6%, respectively) or an ARB (20.5% and 36.8%) more than the other therapeutic classes. For the groups defined by treatment strategy, women, older patients, and patients with CKD or diabetes were initiated on an FEC more often than an FDC or monotherapy, and patients with a diagnosis of hypertension were initiated on an FDC or an FEC more often than monotherapy. Also of note is that the index systolic and diastolic blood pressures were substantially higher in those initiated on an FDC (154 and 94 mm Hg, respectively) compared with those initiated on an FEC (148 and 86 mm Hg, respectively) or monotherapy (148 and 90 mm Hg, respectively). Table 4 presents the frequencies and proportions of patients initiated on FDC or FEC treatment strategies by different therapeutic class combinations. Although similar numbers of patients were initiated on an FDC (n ϭ 795) as an FEC (n ϭ 712), some combination of an ACEI plus a thiazide or ARB plus a thiazide accounted for 81% of those initiated on an FDC, whereas the distribution among 2-drug combinations was much more heterogeneous for those started on an FEC. Table 5 presents the unadjusted and risk-adjusted changes in blood pressure and goal attainment rates for patients initiated on a monotherapy. All 5 therapeutic classes were efficacious in reducing blood pressure with remarkably similar average reductions. There were no significant differences in the unadjusted average systolic blood pressure reductions and only 2 statistically significant (albeit questionably clinically significant) differences after risk adjustment (both Ͻ1.0 mm Hg). The unadjusted average diastolic blood pressure reductions also were similar, with only a single significant differ- ence (between ACEI and thiazide), albeit in reverse, after risk adjustment. However, although statistically significant, these differences were small (unadjusted 1.5 mm Hg; risk-adjusted 0.3 mm Hg).
Antihypertensive Therapeutic Class Outcomes
Patients initiated on either an ACEI or ␤-blocker had significantly higher rates of unadjusted and adjusted goal attainment than patients initiated on a thiazide. Data are number (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ␤-blocker, cardioselective ␤-blocker; CCB, calcium channel blocker; thiazide, thiazide and thiazidelike diuretics. Data are mean (standard deviation) unless otherwise indicated. *Unadjusted P values were from analysis of variance or logistic regression, whereas risk-adjusted P values were from analysis of covariance or logistic regression. † ACEI vs thiazide, P Ͻ .001. ‡ ACEI vs CCB, P ϭ .04. § ACEI vs thiazide, P ϭ .02. ʈ ␤-blocker vs thiazide, P ϭ .003. ¶ ␤-blocker vs thiazide, P ϭ .01. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; thiazide, thiazide and thiazide-like diuretics.
Antihypertensive Treatment Strategy Outcomes
Discussion
This study found that patients receiving care from 33 primary care clinics and who were initiated on 1 of 5 antihypertensive therapeutic classes as monotherapy had remarkably similar average reductions in blood pressure at follow-up (Table 5) . These results are consistent with those found in a metaanalysis of 354 randomized, double-blind trials, which reported little difference in mean placebocorrected reduction in blood pressure across the same 5 therapeutic classes. 16 Our results extend this meta-analysis of efficacy studies done under strictly controlled conditions to the real world of effectiveness in daily practice.
Despite similar reductions in blood pressure across therapeutic classes, patients initiated on ACEIs and ␤-blockers had higher rates of JNC7 goal attainment than patients initiated on thiazide, even after adjusting for patient risk factors. The results of our study cannot be directly compared with those of the Treatment of Mild Hypertension Study, 17 ALLHAT, 18 or Materson et al; 19 these evaluated efficacy by individual agents, whereas we evaluated effectiveness by therapeutic class. In addition, response to therapeutic classes has been shown to vary by race, 19 and racial distributions are likely to be different between studies. Unfortunately, we did not have adequate racial data to adjust for this factor.
We also observed that primary care patients initiated on an FDC had considerably larger reductions in blood pressure and higher goal attainment rates at follow-up than patients initiated on monotherapy (Table 6 ). These results confirm those observed in short-term, randomized clinical efficacy studies and 2 recent observational studies, all of which showed that patients initiated on an FDC obtain better control of their blood pressure than patients initiated on monotherapy alone. [7] [8] [9] 20, 21 However, both of the observational studies also demonstrated superior effectiveness in blood pressure control in patients initiated on an FEC when compared with patients on monotherapy, whereas there was little difference between these 2 treatment strategies observed in the present study. The lack of improved blood pressure control in patients initiated on an FEC could be due to the inclusion of combinations that have been identified by the American Society of Hypertension as being less effective (eg, ACEI and ␤-blocker, ARB and ␤-blocker, and ACEI and ARB). 22 Another difference between the present study and the 2 observational studies is that the latter allowed for therapeutic classes to be added and dosages to be changed, while the present study did not. In addition, several studies have shown that patients taking an FDC have improved adherence over patients taking an FEC, which might further explain the Data are mean (standard deviation) unless otherwise indicated. *Unadjusted P values were calculated using analysis of variance or logistic regression, whereas risk-adjusted P values were from analysis of covariance or logistic regression. FDC, fixed-dose combination; FEC, free-equivalent combination.
differences seen in our study. 10, 11 Finally, the current study found that patients initiated on an FDC had larger reductions in blood pressure and superior rates of blood pressure control when compared with patients initiated on an FEC, which is similar to a report by Egan et al. 21 Effective treatment of high blood pressure is the key therapeutic strategy shown to reduce hypertension-related MACEs. However, hypertension frequently remains uncontrolled in the general population, and most patients require the combination of Ն2 drugs to reach recommended blood pressure goals. 6 The American Society of Hypertension recently published a position paper recommending the routine use of combination therapy to achieve blood pressure targets and classifying combinations as preferred, acceptable, or less effective. 22 The use of a combination of drugs from complementary classes at low doses has been shown to be more effective at lowering blood pressure than increasing the dose of a single agent. 23 The use of low-dose combinations could potentially improve overall tolerability since most side effects of antihypertensive agents are dose-dependent and often drug-specific. While these benefits should apply regardless of whether they were initiated as an FDC or FEC, several studies have shown that patients taking an FDC have improved adherence over patients receiving an FEC since patient adherence is inversely related to the number of pills prescribed. 10, 11 The oft-stated disadvantage of FDCs has been their inability to independently titrate the doses of the component drugs along with higher cost because of the limited availability of generic FDCs. However, if goal attainment is better, the need for titration is lessened.
The strengths of this study include the use of patients from clinical practices, which allows for comparisons of initial hypertension treatment strategies and therapeutic classes outside of a research-intensive setting such as is seen in clinical trials; a geographically diverse sample of primary care clinics; a relatively large sample size; and the ability to adjust for differences in patient characteristics. However, there were several limitations to the study: (1) the observational nature of the study compared with a randomized clinical trial, which could lead to selection biases in the choice of treatments for the patients and residual confounding even after statistical adjustment for some important variables; (2) the inability to adjust for patient race/ ethnicity, which had been shown to be associated with hypertension treatment; (3) the lack of prescription fulfillment data and pill counts or use of other techniques to monitor pills consumed by the patient; and (4) the lack of data on dose and dosing frequency.
Conclusions
Patients initiated on any of the 5 antihypertensive therapeutic classes as a monotherapy had similar reductions in blood pressure, while patients initiated on ACEIs and ␤-blockers had slightly higher rates of blood pressure control than patients initiated on a thiazide. The use of FDCs as initial therapy is more effective in the control of hypertension than monotherapy or FECs.
